Catalyst Wire Dossier Catalyst Wire Dossier

Alirocumab (SAR236553/REGN727)

alirocumab · Sanofi/Regeneron
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Alirocumab (SAR236553/REGN727), covering 2013-06-28 to 2013-06-28. Get the full timeline:

Most recent: Clinical Trial Update: Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727) [Phase 1]

See pricing